Nanosyrinx Ltd
NanoSyrinx is a discovery stage synthetic biology company developing a next-generation platform technology for targeted intracellular delivery of biological molecules. Their mission is to unlock the interior of the cell and the therapeutic opportunities within, by enabling targeted, intracellular delivery of protein therapeutics using a novel 'Nanosyringe' platform. The company was founded in 2020 and is backed by prominent investors including Octopus Ventures, BGF, MVentures, Eli Lilly and Company, IQ Capital, Meltwind, Pioneer Group, and UKI2S. NanoSyrinx aims to create a revolution in biologic drug delivery, addressing the challenge of delivering therapeutics into cells effectively and specifically.
Industries
Nr. of Employees
small (1-50)
Nanosyrinx Ltd
Unit 27D, The Venture Centre, University of Warwick Science Park, Coventry, CV47EZ
Products
Protein-based intracellular delivery platform
A synthetic-biology derived platform designed to transport peptide and protein payloads into the cytosol of target cells, enabling access to intracellular targets that are otherwise difficult to drug.
Protein-based intracellular delivery platform
A synthetic-biology derived platform designed to transport peptide and protein payloads into the cytosol of target cells, enabling access to intracellular targets that are otherwise difficult to drug.
Services
Design and execution of in vitro assays, ex vivo cell engineering workflows and in vivo proof-of-concept studies to validate delivery candidates and support target selection.
Development of scalable microbial fermentation and upstream manufacturing processes with a focus on GMP compatibility and regulatory readiness.
Early-stage discovery workflows to identify and prioritise biologic delivery candidates for preclinical development.
Provision of collaborative engagement with industry partners, accelerator programmes and access to shared laboratory infrastructure and mentorship.
Design and execution of in vitro assays, ex vivo cell engineering workflows and in vivo proof-of-concept studies to validate delivery candidates and support target selection.
Development of scalable microbial fermentation and upstream manufacturing processes with a focus on GMP compatibility and regulatory readiness.
Early-stage discovery workflows to identify and prioritise biologic delivery candidates for preclinical development.
Provision of collaborative engagement with industry partners, accelerator programmes and access to shared laboratory infrastructure and mentorship.
Expertise Areas
- Intracellular delivery of biologic therapeutics
- Synthetic biology platform development
- Protein engineering for delivery
- Preclinical translational biology
Key Technologies
- Synthetic biology
- Protein engineering
- Non-viral intracellular delivery
- Microbial fermentation scale-up
News & Updates
Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities.
Members from the NanoSyrinx team will be presenting data from internal developments and collaborations at upcoming conferences.
Round co-led by BGF, Octopus Ventures, M Ventures, with support from Eli Lilly and Company, IQ Capital, and Meltwind. Edwin Moses appointed as Chairman to support the company's technology platform and strategic growth.
Recognized at the ICURe Celebration & Showcase event for groundbreaking technology with potential to impact biologic therapeutics market.
NanoSyrinx was awarded the 2022 AbbVie UK Golden Ticket, gaining access to lab space, support from AbbVie scientists, and networking opportunities.
Ben Miles from Spin-up Science featured NanoSyrinx in a video discussing its potential to change medicine.
Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities.
Members from the NanoSyrinx team will be presenting data from internal developments and collaborations at upcoming conferences.
Round co-led by BGF, Octopus Ventures, M Ventures, with support from Eli Lilly and Company, IQ Capital, and Meltwind. Edwin Moses appointed as Chairman to support the company's technology platform and strategic growth.
Recognized at the ICURe Celebration & Showcase event for groundbreaking technology with potential to impact biologic therapeutics market.
NanoSyrinx was awarded the 2022 AbbVie UK Golden Ticket, gaining access to lab space, support from AbbVie scientists, and networking opportunities.
Ben Miles from Spin-up Science featured NanoSyrinx in a video discussing its potential to change medicine.